Kemwell and RevOpsis Announce Strategic CDMO Partnership

• Kemwell Biopharma and RevOpsis Therapeutics have entered a strategic manufacturing partnership to develop RevOpsis’ lead candidate, RO-104.

• This collaboration aims to expedite the transition from preclinical to clinical trials for RO-104, a tri-specific biologic for treating neovascular age-related macular degeneration (nAMD).

RevOpsis Therapeutics and Kemwell Biopharma Pvt. Ltd. have entered a strategic partnership to accelerate the development of RevOpsis’ lead candidate, RO-104, for the treatment of neovascular age-related macular degeneration (nAMD). The collaboration, announced on June 17, 2024, leverages Kemwell’s contract manufacturing expertise and RevOpsis’ proprietary Rev-Mod platform.

RO-104 is a novel tri-specific biologic targeting three dominant angiogenic pathways (VEGF-A, VEGF-C, Ang-2) implicated in nAMD, a leading cause of blindness globally. Under this agreement, Kemwell will be responsible for manufacturing RO-104, facilitating the transition from preclinical activities to first-in-human clinical trials.

“Partnering with Kemwell is a pivotal step in accelerating the development of our lead candidate, RO-104,” said Ram Bhandari, MD, Co-founder and Interim CEO of RevOpsis. “Kemwell’s exemplary track record in high-quality biologics manufacturing and their efficiency in reducing timelines, combined with our proprietary Rev-Mod platform, ensures we can deliver transformative therapies to patients efficiently.”

Anurag Bagaria, CEO of Kemwell Biopharma, echoed this sentiment: “We are excited to collaborate with RevOpsis to manufacture and commercialize RO-104. Our expertise in complex protein manufacturing, coupled with RevOpsis’ innovative therapeutic approaches, holds great promise for advancing the treatment of retinal vascular diseases.”

This partnership aims to reduce the complexity and timelines of managing early GMP manufacturing processes by integrating RevOpsis’ multispecific biologics platform with Kemwell’s biologics development and manufacturing expertise. The collaboration is expected to significantly expedite therapeutic discovery to IND submission timelines, providing a crucial development solution for RevOpsis’ pipeline.